NewAmsterdam's pooled Phase 3 data; C4 seeks partners for solid tumor degrader

Plus, news about Vivo Capital, Arcus Biosciences, Rigel and Voyager Therapeutics: NewAmsterdam shares pooled Phase 3 data: The company’s experimental CETP inhibitor obicetrapib reduced lipoprotein (a) levels by a median of ...

Related Posts

Caribou lays off 32% of staff, cuts lupus program

Apr 24, 2025  0

Amicus grabs Dimerix’s rare kidney disease drug for $30...

May 1, 2025  0

Novartis Q1 earnings: Company raises 2025 bar after bea...

Apr 29, 2025  0

Comments

Name

Email

Comment

Post Comment